PresseBox
Press release BoxID: 799986 (ARTES Biotechnology GmbH)
  • ARTES Biotechnology GmbH
  • Elisabeth-Selbert-Str. 9
  • 40764 Langenfeld
  • http://www.artes-biotechnology.com
  • Contact person
  • Melanie Piontek
  • +49 (2173) 275870

ARTES Biotechnology and Biosphere announce collaboration

(PresseBox) (Langenfeld, ) ARTES Biotechnology, specialized in microbial cell line and process development for recombinant protein production and technology provider for high-quality biotechnological processes, join forces with the well-established contract manufacturing company Biosphere. Aim of this preferred cooperation is to offer a full range of services, starting from cell line generation up to industrial scale manufacturing in one package. The combination of the different expertise, know-how and infrastructure of the two companies will flow directly into one common offer. This offer addresses customers who are looking for development of enzymes and proteins currently applied in the pharmaceutical, food and fine chemical sector.

About Biosphere Srl:
Biosphere is an Italian Contract R&D and Manufacturing Company specialized in the production of microbial biomass, metabolites, proteins, especially enzymes.
Biosphere has a strong expertise in the process development and production of microbial enzymes that are currently applied as biocatalysts in several industrial processes.
The R&D and production facility is designed to perform fermentation processes from lab to pilot and pre-industrial scale (1.500 L), and for the recovery and purification of the products.

For more information, please visit http://www.biospheresrl.com.

 

Website Promotion

ARTES Biotechnology GmbH

ARTES Biotechnology GmbH is a pharmaceutical technology provider specialized in recombinant protein production, process and vaccine development from microbial expression systems and markets the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression. ARTES platform is applicable for large and multimeric antigens and able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850-sqm S1 facilities in Langenfeld.

For more information, please visit http://www.artes-biotechnology.com